The role of immunoenzymatic therapy in the management of vestibulodynia associated with painful bladder syndrome ()
ABSTRACT
Background: Vestibulodynia (VBD)
and painful bladder syndrome (PBS) are two common and often concomitant
conditions. Objective: To assess the effectiveness of an enzymatic
combination of papain, bromelain, trypsin, chymotrypsin and quercetin in the
supportive treatment of VBD/PBS, patients underwent TENS + amitriptyline and
pregabalin therapy as a multimodal treatment strategy. Method: 40 patients were randomly assigned to receive a
systemic therapy: amitriptyline + pregabalin (Group A) versus
amitriptyline + Pregabalin plus a systemic enzyme preparation (Group B).
All patients received a transcutaneous electric nerve stimulation (TENS)
therapy in a self-administered domiciliary protocol. Results: The VAS and the
dyspareunia score after the treatment showed a significant difference in the two
groups (VAS: Group A difference of 4.3, Group B difference of 3.1, p = 0.005;
dyspareunia: Group A and Group B 1.8 vs. 0.8, p = 0.005). Conclusion: The positive
results of our study prove the utility effectiveness of an enzyme combination
to decrease and normalize the biomarkers of inflammation in VBD and PBS patients
in a multimodal approach.
Share and Cite:
Murina, F. , Felice, R. , Francesco, S. and Mantegazza, V. (2013) The role of immunoenzymatic therapy in the management of vestibulodynia associated with painful bladder syndrome.
Open Journal of Obstetrics and Gynecology,
3, 16-19. doi:
10.4236/ojog.2013.34A003.